Report cover image

Insulin Glargine and Lispro Industry Research Report 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 123 Pages
SKU # APRC20352774

Description

Summary

According to APO Research, the global Insulin Glargine and Lispro market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Insulin Glargine and Lispro is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Insulin Glargine and Lispro is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Insulin Glargine and Lispro is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Insulin Glargine and Lispro include Sanofi S.A, Merck & Co., Eli Lilly and Company, Wockhardt Ltd., SAJA Pharmaceuticals, Novo Nordisk A/S, Julphar Diabetes LLC, Gan & Lee Pharmaceutical Ltd. and Cipla Limited, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Insulin Glargine and Lispro, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Insulin Glargine and Lispro.

The report will help the Insulin Glargine and Lispro manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Insulin Glargine and Lispro market size, estimations, and forecasts are provided in terms of sales volume (L) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Insulin Glargine and Lispro market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Insulin Glargine and Lispro Segment by Company

Sanofi S.A
Merck & Co.
Eli Lilly and Company
Wockhardt Ltd.
SAJA Pharmaceuticals
Novo Nordisk A/S
Julphar Diabetes LLC
Gan & Lee Pharmaceutical Ltd.
Cipla Limited
Biocon Limited
Insulin Glargine and Lispro Segment by Type

Branded Drug
Biosimilar Drug
Insulin Glargine and Lispro Segment by Application

Type I Dibetes
Type II Dibetes
Insulin Glargine and Lispro Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Insulin Glargine and Lispro market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Insulin Glargine and Lispro and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Insulin Glargine and Lispro.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Insulin Glargine and Lispro manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Insulin Glargine and Lispro by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Insulin Glargine and Lispro in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Table of Contents

123 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Insulin Glargine and Lispro Market Size (2020-2031)
2.2.2 Global Insulin Glargine and Lispro Sales (2020-2031)
2.2.3 Global Insulin Glargine and Lispro Market Average Price (2020-2031)
2.3 Insulin Glargine and Lispro by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Branded Drug
2.3.3 Biosimilar Drug
2.4 Insulin Glargine and Lispro by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Type I Dibetes
2.4.3 Type II Dibetes
3 Market Competitive Landscape by Manufacturers
3.1 Global Insulin Glargine and Lispro Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Insulin Glargine and Lispro Sales (L) of Manufacturers (2020-2025)
3.3 Global Insulin Glargine and Lispro Revenue of Manufacturers (2020-2025)
3.4 Global Insulin Glargine and Lispro Average Price by Manufacturers (2020-2025)
3.5 Global Insulin Glargine and Lispro Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Insulin Glargine and Lispro, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Insulin Glargine and Lispro, Product Type & Application
3.8 Global Manufacturers of Insulin Glargine and Lispro, Established Date
3.9 Global Insulin Glargine and Lispro Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Sanofi S.A
4.1.1 Sanofi S.A Company Information
4.1.2 Sanofi S.A Business Overview
4.1.3 Sanofi S.A Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Sanofi S.A Insulin Glargine and Lispro Product Portfolio
4.1.5 Sanofi S.A Recent Developments
4.2 Merck & Co.
4.2.1 Merck & Co. Company Information
4.2.2 Merck & Co. Business Overview
4.2.3 Merck & Co. Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2020-2025)
4.2.4 Merck & Co. Insulin Glargine and Lispro Product Portfolio
4.2.5 Merck & Co. Recent Developments
4.3 Eli Lilly and Company
4.3.1 Eli Lilly and Company Company Information
4.3.2 Eli Lilly and Company Business Overview
4.3.3 Eli Lilly and Company Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Eli Lilly and Company Insulin Glargine and Lispro Product Portfolio
4.3.5 Eli Lilly and Company Recent Developments
4.4 Wockhardt Ltd.
4.4.1 Wockhardt Ltd. Company Information
4.4.2 Wockhardt Ltd. Business Overview
4.4.3 Wockhardt Ltd. Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Wockhardt Ltd. Insulin Glargine and Lispro Product Portfolio
4.4.5 Wockhardt Ltd. Recent Developments
4.5 SAJA Pharmaceuticals
4.5.1 SAJA Pharmaceuticals Company Information
4.5.2 SAJA Pharmaceuticals Business Overview
4.5.3 SAJA Pharmaceuticals Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2020-2025)
4.5.4 SAJA Pharmaceuticals Insulin Glargine and Lispro Product Portfolio
4.5.5 SAJA Pharmaceuticals Recent Developments
4.6 Novo Nordisk A/S
4.6.1 Novo Nordisk A/S Company Information
4.6.2 Novo Nordisk A/S Business Overview
4.6.3 Novo Nordisk A/S Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2020-2025)
4.6.4 Novo Nordisk A/S Insulin Glargine and Lispro Product Portfolio
4.6.5 Novo Nordisk A/S Recent Developments
4.7 Julphar Diabetes LLC
4.7.1 Julphar Diabetes LLC Company Information
4.7.2 Julphar Diabetes LLC Business Overview
4.7.3 Julphar Diabetes LLC Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2020-2025)
4.7.4 Julphar Diabetes LLC Insulin Glargine and Lispro Product Portfolio
4.7.5 Julphar Diabetes LLC Recent Developments
4.8 Gan & Lee Pharmaceutical Ltd.
4.8.1 Gan & Lee Pharmaceutical Ltd. Company Information
4.8.2 Gan & Lee Pharmaceutical Ltd. Business Overview
4.8.3 Gan & Lee Pharmaceutical Ltd. Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2020-2025)
4.8.4 Gan & Lee Pharmaceutical Ltd. Insulin Glargine and Lispro Product Portfolio
4.8.5 Gan & Lee Pharmaceutical Ltd. Recent Developments
4.9 Cipla Limited
4.9.1 Cipla Limited Company Information
4.9.2 Cipla Limited Business Overview
4.9.3 Cipla Limited Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Cipla Limited Insulin Glargine and Lispro Product Portfolio
4.9.5 Cipla Limited Recent Developments
4.10 Biocon Limited
4.10.1 Biocon Limited Company Information
4.10.2 Biocon Limited Business Overview
4.10.3 Biocon Limited Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Biocon Limited Insulin Glargine and Lispro Product Portfolio
4.10.5 Biocon Limited Recent Developments
5 Global Insulin Glargine and Lispro Market Scenario by Region
5.1 Global Insulin Glargine and Lispro Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Insulin Glargine and Lispro Sales by Region: 2020-2031
5.2.1 Global Insulin Glargine and Lispro Sales by Region: 2020-2025
5.2.2 Global Insulin Glargine and Lispro Sales by Region: 2026-2031
5.3 Global Insulin Glargine and Lispro Revenue by Region: 2020-2031
5.3.1 Global Insulin Glargine and Lispro Revenue by Region: 2020-2025
5.3.2 Global Insulin Glargine and Lispro Revenue by Region: 2026-2031
5.4 North America Insulin Glargine and Lispro Market Facts & Figures by Country
5.4.1 North America Insulin Glargine and Lispro Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Insulin Glargine and Lispro Sales by Country (2020-2031)
5.4.3 North America Insulin Glargine and Lispro Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.5 Europe Insulin Glargine and Lispro Market Facts & Figures by Country
5.5.1 Europe Insulin Glargine and Lispro Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Insulin Glargine and Lispro Sales by Country (2020-2031)
5.5.3 Europe Insulin Glargine and Lispro Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Netherlands
5.6 Asia Pacific Insulin Glargine and Lispro Market Facts & Figures by Country
5.6.1 Asia Pacific Insulin Glargine and Lispro Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Insulin Glargine and Lispro Sales by Country (2020-2031)
5.6.3 Asia Pacific Insulin Glargine and Lispro Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Southeast Asia
5.7 South America Insulin Glargine and Lispro Market Facts & Figures by Country
5.7.1 South America Insulin Glargine and Lispro Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Insulin Glargine and Lispro Sales by Country (2020-2031)
5.7.3 South America Insulin Glargine and Lispro Revenue by Country (2020-2031)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.7.7 Colombia
5.8 Middle East and Africa Insulin Glargine and Lispro Market Facts & Figures by Country
5.8.1 Middle East and Africa Insulin Glargine and Lispro Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Insulin Glargine and Lispro Sales by Country (2020-2031)
5.8.3 Middle East and Africa Insulin Glargine and Lispro Revenue by Country (2020-2031)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global Insulin Glargine and Lispro Sales by Type (2020-2031)
6.1.1 Global Insulin Glargine and Lispro Sales by Type (2020-2031) & (L)
6.1.2 Global Insulin Glargine and Lispro Sales Market Share by Type (2020-2031)
6.2 Global Insulin Glargine and Lispro Revenue by Type (2020-2031)
6.2.1 Global Insulin Glargine and Lispro Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Insulin Glargine and Lispro Revenue Market Share by Type (2020-2031)
6.3 Global Insulin Glargine and Lispro Price by Type (2020-2031)
7 Segment by Application
7.1 Global Insulin Glargine and Lispro Sales by Application (2020-2031)
7.1.1 Global Insulin Glargine and Lispro Sales by Application (2020-2031) & (L)
7.1.2 Global Insulin Glargine and Lispro Sales Market Share by Application (2020-2031)
7.2 Global Insulin Glargine and Lispro Revenue by Application (2020-2031)
7.2.1 Global Insulin Glargine and Lispro Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Insulin Glargine and Lispro Revenue Market Share by Application (2020-2031)
7.3 Global Insulin Glargine and Lispro Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Insulin Glargine and Lispro Value Chain Analysis
8.1.1 Insulin Glargine and Lispro Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Insulin Glargine and Lispro Production Mode & Process
8.2 Insulin Glargine and Lispro Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Insulin Glargine and Lispro Distributors
8.2.3 Insulin Glargine and Lispro Customers
9 Global Insulin Glargine and Lispro Analyzing Market Dynamics
9.1 Insulin Glargine and Lispro Industry Trends
9.2 Insulin Glargine and Lispro Industry Drivers
9.3 Insulin Glargine and Lispro Industry Opportunities and Challenges
9.4 Insulin Glargine and Lispro Industry Restraints
10 Report Conclusion
11 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.